Oppenheimer Holdings Stock News

Oppenheimer reaffirmed their hold rating on shares of Oracle (NYSE:ORCL) in a research note issued to investors on Friday morning, Analyst Price Targets reports. A number of other equities analysts also recently issued reports on the stock. UBS Group increased their price target on shares of Oracle from $86.00 to $94.00 and gave the company [] The post Oracles (ORCL) Hold Rating Reaffirmed at Oppenheimer appeared first on ETF Daily News .

Oppenheimer restated their hold rating on shares of Oracle (NYSE:ORCL) in a research note published on Friday morning, PriceTargets.com reports. Several other brokerages have also recently issued reports on ORCL. BMO Capital Markets raised their target price on shares of Oracle from $88.00 to $100.00 and gave the stock a market perform rating in a […]

Oppenheimer initiated coverage on shares of UserTesting (NYSE:USER) in a research report report published on Monday morning, PriceTargets.com reports. The firm issued an outperform rating and a $14.00 price objective on the stock. Separately, Piper Sandler started coverage on shares of UserTesting in a research note on Monday. They issued an overweight rating and a […] The post UserTesting (NYSE:USER) Now Covered by Oppenheimer appeared first on ETF Daily News .

UBS Group assumed coverage on shares of Bank of America (NYSE:BAC) in a research note published on Friday, Analyst Ratings Network reports. The brokerage issued a buy rating and a $64.00 price target on the financial services provider’s stock. BAC has been the topic of a number of other research reports. Oppenheimer boosted their price […]

CVS Health Co. (NYSE:CVS) – Oppenheimer upped their FY2021 earnings estimates for CVS Health in a report released on Thursday, December 9th. Oppenheimer analyst M. Wiederhorn now anticipates that the pharmacy operator will post earnings per share of $8.03 for the year, up from their prior estimate of $7.98. Oppenheimer also issued estimates for CVS […]

Perion Network Ltd. (NASDAQ:PERI) – Equities researchers at Oppenheimer increased their FY2021 EPS estimates for Perion Network in a research report issued on Thursday, December 9th. Oppenheimer analyst J. Helfstein now forecasts that the technology company will earn $0.98 per share for the year, up from their previous forecast of $0.89. Oppenheimer has a “Outperform” […] The post Perion Network Ltd. (NASDAQ:PERI) Expected to Earn FY2021 Earnings of $0.98 Per Share appeared first on ETF Daily News .

Heading into year’s end, the Street’s professional analysts are busy putting together their predictive models, working to give investors an idea just where the mark…

Atlantic Securities upgraded shares of Yum! Brands (NYSE:YUM) from a neutral rating to an overweight rating in a research note issued to investors on Thursday, PriceTargets.com reports. The firm currently has $151.00 price target on the restaurant operators stock. A number of other equities analysts also recently commented on YUM. Oppenheimer downgraded Yum! Brands from [] The post Yum! Brands (NYSE:YUM) Raised to Overweight at Atlantic Securities appeared first on ETF Daily News .

The Lovesac Company (NASDAQ:LOVE) Oppenheimer lifted their FY2022 EPS estimates for Lovesac in a note issued to investors on Thursday, December 9th. Oppenheimer analyst B. Nagel now anticipates that the company will post earnings per share of $1.29 for the year, up from their prior forecast of $0.64. Oppenheimer currently has a Outperform rating []

Angion Biomedica (NASDAQ:ANGN) had its price objective reduced by analysts at Oppenheimer from $15.00 to $8.00 in a report issued on Friday, The Fly reports. The firm presently has an outperform rating on the stock. Oppenheimers price target would indicate a potential upside of 206.51% from the companys current price. A number of other equities []

Conns, Inc. (NASDAQ:CONN) Oppenheimer decreased their FY2022 EPS estimates for shares of Conns in a report issued on Wednesday, December 8th. Oppenheimer analyst B. Nagel now anticipates that the specialty retailer will earn $3.90 per share for the year, down from their previous forecast of $4.06. Oppenheimer also issued estimates for Conns Q4 2022 []

The Lovesac Company (NASDAQ:LOVE) Equities researchers at Oppenheimer issued their Q2 2023 EPS estimates for Lovesac in a research report issued to clients and investors on Thursday, December 9th. Oppenheimer analyst B. Nagel expects that the company will earn $0.16 per share for the quarter. Oppenheimer has a Outperform rating and a $95.00 price []

Oppenheimer (NYSE: OPY) is one of 54 public companies in the Security brokers & dealers industry, but how does it compare to its competitors? We will compare Oppenheimer to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and valuation. Profitability This table compares Oppenheimer and its competitors []

Oppenheimer upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a market perform rating to an outperform rating in a research note issued to investors on Friday morning, Analyst Ratings Network reports. Oppenheimer currently has $31.00 target price on the biotechnology companys stock, down from their previous target price of $33.00. Other equities research analysts have []

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by stock analysts at Oppenheimer from a market perform rating to an outperform rating in a research report issued to clients and investors on Thursday, Analyst Price Targets reports. The firm presently has a $125.00 price objective on the biotechnology companys stock. Oppenheimers price objective indicates a potential upside of []